Tech Company Financing Transactions
Elusys Therapeutics Funding Round
MedImmune Ventures, Crescendo Ventures and EW Healthcare Partners participated in a $23 million Series D funding round for Elusys Therapeutics. The round was recorded on 7/13/2006.
Transaction Overview
Company Name
Announced On
7/13/2006
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series D
Investors
Proceeds Purpose
This new venture funding will accelerate the development of our HP Antibody pipeline targeting drug resistant infections.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4 Century Dr. 260
Parsippany, NJ 07054
USA
Parsippany, NJ 07054
USA
Phone
Website
Email Address
Overview
Elusys Therapeutics is a private company focused on the development of antibody therapeutics for the treatment of infectious disease. For over 10 years, Elusys has been engaged in development of new therapies for the treatment of anthrax exposure following a natural or intentional release of anthrax spores.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elizabeth Posillico
VP - Bus. Development
Jeremy Middleton
VP - Finance
Vera Wong
VP - Manufacturing
James Porter
VP - Regulatory Affairs
Robin Conrad
Browse more venture capital transactions:
Prev: 7/13/2006: Radianse venture capital transaction
Next: 7/14/2006: Alert Logic venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs